A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027)
MK-2870-027
Phase 2 other active
Quick answer
A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027) for Intermediate-risk Non-muscle Invasive Bladder Cancer is a Phase 2 program (other) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Intermediate-risk Non-muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Modality
- other
- Status
- active